Litigation Details for Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)
✉ Email this page to a colleague
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-06-19 |
| Court | District Court, N.D. New York | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | David N. Hurd |
| Jury Demand | Both | Referred To | Christian F. Hummel |
| Patents | 9,220,631 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.
The biologic drugs covered by the patent cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-06-19 | 1 | Complaint | Regeneron”) for infringement of U.S. Patent No. 9,220,631 (“the ’631 patent”). …unlawfully uses Novartis’s patented syringe technology and infringes the ’631 patent. …the United States Patent and Trademark Office duly and legally issued the ’631 patent, entitled “Syringe…copy of the ’631 patent is attached as Exhibit A. 13. The ’631 patent is valid and presumed…’631 patent necessary to bring this action, including the exclusive right to enforce the patent in the | External link to document |
| 2022-11-07 | 163 | 6, 11-13, 17, and 21-25 of U.S. Patent No. 9,220,631 (“the ’631 Patent”); WHEREAS, no trial dates…all claims of the ’631 Patent; WHEREAS, on October 25, 2022, the Patent Trial and Appeal Board…Technology LLC (collectively “Novartis”) brought this patent infringement action accusing Defendant Regeneron…Court. WHEREAS, on October 26, 2021, the Patent Trial and Appeal Board (“PTAB”) instituted an …in IPR2021-00816 finding all claims of the ’631 Patent unpatentable as obvious under 35 U.S.C. § 103; | External link to document | |
| 2020-07-28 | 24 | Exhibit A | 9,220,631 (‘‘the ’631 patent’’). The …properly certain claims of U.S. Patent No. … 1–6 and 11–26 of the ’631 patent, and date of service by the … 19 June 2020 1:20-cv-00690 830 Patent Both District Court, N.D. New York | External link to document |
| 2021-04-20 | 38 | Exhibit(s) 1 - Complainants' Unopposed Motion to Terminate | Regeneron directly infringed U.S. Patent No. 9,220,631 (the “Asserted Patent”) and that Novartis satisfied… continued flaunting of Novartis’s valid patent rights. Novartis’s Pre-Hr’g Br. at 6 (EDIS Doc…Order No. 31. Novartis maintains that the Asserted Patent is valid and that Regeneron cannot prove otherwise… 19 June 2020 1:20-cv-00690 830 Patent Both District Court, N.D. New York | External link to document |
| 2020-06-22 | 4 | Determination of an Action regarding patent and/or trademark number(s) 9,220,631. (dpk) (Entered: 06/23/2020) … 19 June 2020 1:20-cv-00690 830 Patent Both District Court, N.D. New York | External link to document | |
| 2021-07-11 | 54 | Dismiss for Failure to State a Claim | Exhibit(s) 1 to Cook Declaration - U.S. Patent No. 9,220,631, # 4 Exhibit(s) 2 to Cook Declaration - … 19 June 2020 1:20-cv-00690 830 Patent Both District Court, N.D. New York | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
